{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:10:19Z","timestamp":1792195819857,"version":"4.4.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005296","name":"American Association of Pharmaceutical Scientists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005296","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005296","name":"American Association of Pharmaceutical Scientists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005296","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.xphs.2022.01.011","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T09:43:05Z","timestamp":1642930985000},"page":"887-902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Stress Factors in Primary Packaging, Transportation and Handling of Protein Drug Products and Their Impact on Product Quality"],"prefix":"10.1016","volume":"111","author":[{"given":"Linda O.","family":"Narhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4764-1345","authenticated-orcid":false,"given":"Danny K.","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Twinkle. R.","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Jagannathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Jiskoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alavattam","family":"Sreedhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3641-3988","authenticated-orcid":false,"given":"Tapan K.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0001","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.xphs.2019.09.023","article-title":"Stress factors in mAb drug substance production processes: critical assessment of impact on product quality and control strategy","volume":"109","author":"Das","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.01.011_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2021.09.030","article-title":"Stress factors in protein drug product manufacturing and their impact on product quality","author":"Das","year":"2022","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2022.01.011_bib0003","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/bp070462h","article-title":"Current perspectives on stability of protein drug products during formulation, fill and finish operations","volume":"24","author":"Rathore","year":"2008","journal-title":"Biotechnol Prog"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0004","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.xphs.2019.10.064","article-title":"Shocking data on parcel shipments of protein solutions","volume":"109","author":"Siska","year":"2020","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2022.01.011_bib0005","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jps.24259","article-title":"Do not drop: mechanical shock in vials causes cavitation, protein aggregation, and particle formation","volume":"104","author":"Randolph","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.01.011_bib0006","series-title":"Standard Practice for Performance Testing of Shipping Containers and Systems","year":"2008"},{"issue":"4","key":"10.1016\/j.xphs.2022.01.011_bib0007","doi-asserted-by":"crossref","first-page":"323","DOI":"10.5731\/pdajpst.2013.00925","article-title":"Novel mechanism of glass delamination in Type 1A borosilicate vials containing frozen protein formulations","volume":"67","author":"Jiang","year":"2013","journal-title":"PDA J Pharm Sci Technol"},{"issue":"2","key":"10.1016\/j.xphs.2022.01.011_bib0008","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jps.24184","article-title":"Effects of syringe material and silicone oil lubrication on the stability of pharmaceutical proteins","volume":"104","author":"Krayukhina","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.01.011_bib0009","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ajoc.2017.07.009","article-title":"Silicone oil droplets following intravitreal bevacizumab injections","volume":"10","author":"Yu","year":"2018","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"7","key":"10.1016\/j.xphs.2022.01.011_bib0010","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1002\/jps.22515","article-title":"Evaluation of the effect of syringe surfaces on protein formulations","volume":"100","author":"Majumdar","year":"2011","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2022.01.011_bib0011","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/jps.23408","article-title":"Ionic strength affects tertiary structure and aggregation propensity of a monoclonal antibody adsorbed to silicone oil-water interfaces","volume":"102","author":"Gerhardt","year":"2013","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2022.01.011_bib0012","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/jphp.12765","article-title":"Immunogenicity of protein aggregates of a monoclonal antibody generated by forced shaking stress with siliconized and nonsiliconized syringes in BALB\/c mice","volume":"69","author":"Uchino","year":"2017","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0013","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.xphs.2015.10.012","article-title":"Evaluation of incremental siliconization levels on soluble aggregates, submicron and subvisible particles in a prefilled syringe product","volume":"105","author":"Bai","year":"2016","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2022.01.011_bib0014","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/jps.20321","article-title":"Silicone oil induced aggregation of proteins","volume":"94","author":"Jones","year":"2005","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2022.01.011_bib0015","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1002\/jps.23328","article-title":"Silicone-oil-based subvisible particles: their detection, interactions, and regulation in prefilled container closure systems for biopharmaceuticals","volume":"101","author":"Felsovalyi","year":"2012","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2022.01.011_bib0016","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1002\/jps.22704","article-title":"Demonstrating the stability of albinterferon alfa-2b in the presence of silicone oil","volume":"100","author":"Auge","year":"2011","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2022.01.011_bib0017","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.xphs.2018.04.005","article-title":"Postproduction handling and administration of protein pharmaceuticals and potential instability issues","volume":"107","author":"Nejadnik","year":"2018","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2022.01.011_bib0018","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/jps.23001","article-title":"Particles in therapeutic protein formulations, Part 1: Overview of analytical methods","volume":"101","author":"Zolls","year":"2012","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-019-0384-0","article-title":"Phase-appropriate application of analytical methods to monitor subvisible particles across the biotherapeutic drug product life cycle","volume":"22","author":"Mathaes","year":"2019","journal-title":"AAPS J"},{"issue":"4","key":"10.1016\/j.xphs.2022.01.011_bib0020","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s11095-010-0297-1","article-title":"Strategies for the assessment of protein aggregates in pharmaceutical biotech product development","volume":"28","author":"den Engelsman","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2022.01.011_bib0021","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.trac.2013.05.005","article-title":"Analytical approaches to assess the degradation of therapeutic proteins","volume":"49","author":"Vasco","year":"2013","journal-title":"TrAC Trends Anal Chem"},{"issue":"11","key":"10.1016\/j.xphs.2022.01.011_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12111112","article-title":"Particle detection and characterization for biopharmaceutical applications: current principles of established and alternative techniques","volume":"12","author":"Gross-Rother","year":"2020","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.xphs.2022.01.011_bib0023","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/jps.21719","article-title":"Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution","volume":"98","author":"Thirumangalathu","year":"2009","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.01.011_bib0024","series-title":"Flurotec Barrier Film Coating","year":"2021"},{"issue":"6","key":"10.1016\/j.xphs.2022.01.011_bib0025","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jclinane.2009.12.006","article-title":"An evidence-based approach to medication preparation for the surgical patient at risk for latex allergy: is it time to stop being stopper poppers?","volume":"22","author":"Heitz","year":"2010","journal-title":"J Clin Anesth"},{"issue":"6","key":"10.1016\/j.xphs.2022.01.011_bib0026","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1067\/mai.2001.115630","article-title":"Natural rubber pharmaceutical vial closures release latex allergens that produce skin reactions","volume":"107","author":"Primeau","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.xphs.2022.01.011_bib0027","series-title":"Prefilled Syringes -Part 4: Glass Barrels for Injectables and Sterilized Subassembled Syringes Ready for Filling","first-page":"11040","year":"2015"},{"key":"10.1016\/j.xphs.2022.01.011_bib0028","series-title":"Prefilled Syringes - Part 6: Plastic Barrels for Injectables","first-page":"11040","year":"2012"},{"key":"10.1016\/j.xphs.2022.01.011_bib0029","first-page":"88","article-title":"How sterilization of primary packaging influences the results of E&L studies","author":"Sogding","year":"2015","journal-title":"Contract Pharma"},{"issue":"4","key":"10.1016\/j.xphs.2022.01.011_bib0030","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0021-9258(18)70197-X","article-title":"Reaction of ethylene oxide with histidine, methionine, and cysteine","volume":"234","author":"Windmueller","year":"1959","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.xphs.2022.01.011_bib0031","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/jps.24257","article-title":"Chemical modifications of therapeutic proteins induced by residual ethylene oxide","volume":"104","author":"Chen","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.01.011_bib0032","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1525-1594.1987.tb02637.x","article-title":"IgE against ethylene oxide-altered human serum albumin (EtO-HSA) as an etiologic agent in allergic reactions of hemodialysis patients","volume":"11","author":"Grammer","year":"1987","journal-title":"Artif Organs"},{"issue":"3","key":"10.1016\/j.xphs.2022.01.011_bib0033","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/0091-6749(91)90387-4","article-title":"A comparison of cutaneous testing and ELISA testing for assessing reactivity to ethylene oxide-human serum albumin in hemodialysis patients with anaphylactic reactions","volume":"87","author":"Grammer","year":"1991","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.xphs.2022.01.011_bib0034","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1002\/jps.23225","article-title":"Particles shed from syringe filters and their effects on agitation-induced protein aggregation","volume":"101","author":"Liu","year":"2012","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.5731\/pdajpst.2015.01009","article-title":"A strategy for the prevention of protein oxidation by drug product in polymer-based syringes","volume":"69","author":"Nakamura","year":"2015","journal-title":"PDA J Pharm Sci Technol"},{"issue":"3","key":"10.1016\/j.xphs.2022.01.011_bib0036","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.xphs.2018.10.049","article-title":"Silicone oil-free polymer syringes for the storage of therapeutic proteins","volume":"108","author":"Werner","year":"2019","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0037","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.xphs.2018.09.029","article-title":"Impact of ethylene oxide sterilization of polymer-based prefilled syringes on chemical degradation of a model therapeutic protein during storage","volume":"108","author":"Funatsu","year":"2019","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2022.01.011_bib0038","first-page":"75","article-title":"Prefilled syringe sterilization - NO2 sterilization: a flexible solution for prefilled syringes","volume":"14","author":"Goulet","year":"2014","journal-title":"Drug Dev and Del"},{"issue":"6","key":"10.1016\/j.xphs.2022.01.011_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130043","article-title":"Nitrogen dioxide sterilization in low-resource environments: a feasibility study","volume":"10","author":"Shomali","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.xphs.2022.01.011_bib0040","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/15459620701329012","article-title":"Inactivation of viruses on surfaces by ultraviolet germicidal irradiation","volume":"4","author":"Tseng","year":"2007","journal-title":"J Occup Environ Hyg"},{"key":"10.1016\/j.xphs.2022.01.011_bib0041","first-page":"43","article-title":"Sterilization methods and the comparison of E-beam sterilization with gamma radiation sterilization","volume":"34","author":"Silindir","year":"2009","journal-title":"FABAD J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2022.01.011_bib0042","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.xphs.2016.12.007","article-title":"Impact of sterilization method on protein aggregation and particle formation in polymer-based syringes","volume":"106","author":"Kiminami","year":"2017","journal-title":"J Pharm Sci"},{"issue":"1-2","key":"10.1016\/j.xphs.2022.01.011_bib0043","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijpharm.2015.02.020","article-title":"Assessment of the effects of sterilization methods on protein drug stability by elucidating decomposition mechanism and material analysis","volume":"484","author":"Nakamura","year":"2015","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2022.01.011_bib0044","series-title":"Ready to Use Glass Vials for Injectables","year":"2021"},{"issue":"9","key":"10.1016\/j.xphs.2022.01.011_bib0045","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1002\/jps.21768","article-title":"Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies","volume":"98","author":"Bee","year":"2009","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2022.01.011_bib0046","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/jps.24069","article-title":"Impact of glass corrosion on drug substance stability","volume":"103","author":"Watkins","year":"2014","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2022.01.011_bib0047","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1208\/s12249-010-9506-9","article-title":"Factors affecting the chemical durability of glass used in the pharmaceutical industry","volume":"11","author":"Iacocca","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2022.01.011_bib0048","series-title":"Questions and Answers on Current Good Manufacturing Practices, Good Guidance Practices, Level 2 Guidance - Control of Components and Drug Product Containers and Closures","year":"2019"},{"issue":"3","key":"10.1016\/j.xphs.2022.01.011_bib0049","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1081\/PDT-100002248","article-title":"Glass vials for small volume parenterals: influence of drug and manufacturing processes on glass delamination","volume":"6","author":"Ennis","year":"2001","journal-title":"Pharm Dev Technol"},{"key":"10.1016\/j.xphs.2022.01.011_bib0050","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10853-006-0156-y","article-title":"Corrosive attack of glass by a pharmaceutical compound","volume":"42","author":"Iacocca","year":"2007","journal-title":"J Mater Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0051","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/10837450903511178","article-title":"Practical fundamentals of glass, rubber, and plastic sterile packaging systems","volume":"15","author":"Sacha","year":"2010","journal-title":"Pharm Dev Technol"},{"issue":"6","key":"10.1016\/j.xphs.2022.01.011_bib0052","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/jps.23973","article-title":"Protein aggregation and particle formation in prefilled glass syringes","volume":"103","author":"Gerhardt","year":"2014","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2022.01.011_bib0053","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1002\/jps.21707","article-title":"Precipitation of a monoclonal antibody by soluble tungsten","volume":"98","author":"Bee","year":"2009","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0054","first-page":"11","article-title":"Root cause analysis of tungsten-induced protein aggregation in pre-filled syringes","volume":"64","author":"Liu","year":"2010","journal-title":"PDA J Pharm Sci Technol"},{"issue":"10","key":"10.1016\/j.xphs.2022.01.011_bib0055","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/jps.22597","article-title":"Effects of surfaces and leachables on the stability of biopharmaceuticals","volume":"100","author":"Bee","year":"2011","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2022.01.011_bib0056","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1111\/j.1523-1755.2005.00340.x","article-title":"The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes","volume":"67","author":"Boven","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.xphs.2022.01.011_bib0057","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jpba.2017.02.039","article-title":"Identification of leachables observed in the size exclusion chromatograms of a low concentration product stored in prefilled syringes","volume":"139","author":"Valente","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.xphs.2022.01.011_bib0058","series-title":"SG Nexa\u00ae: High-Performance Syringe Systems for Biologics","year":"2021"},{"issue":"6","key":"10.1016\/j.xphs.2022.01.011_bib0059","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1208\/s12249-014-0167-y","article-title":"Glass delamination: a comparison of the inner surface performance of vials and pre-filled syringes","volume":"15","author":"Zhao","year":"2014","journal-title":"AAPS PharmSciTech"},{"issue":"4S","key":"10.1016\/j.xphs.2022.01.011_bib0060","first-page":"S1","article-title":"Siliconization of parenteral drug packaging components (Technical Report No. 12)","volume":"42","year":"1988","journal-title":"PDA J Parenteral Sci Technol"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10837450.2014.982825","article-title":"Pre-filled syringes: a review of the history, manufacturing and challenges","volume":"20","author":"Sacha","year":"2015","journal-title":"Pharm Dev Technol"},{"key":"10.1016\/j.xphs.2022.01.011_bib0062","first-page":"1384","article-title":"Cross-linked silicone coatings: a novel prefilled syringe technology that reduces subvisible particles and maintains compatibility with biologics","volume":"102","author":"Depaz","year":"2016","journal-title":"Pharma Biotechnol"},{"issue":"12","key":"10.1016\/j.xphs.2022.01.011_bib0063","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1016\/j.xphs.2016.08.031","article-title":"Silicone migration from baked-on silicone layers. particle characterization in placebo and protein solutions","volume":"105","author":"Funke","year":"2016","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2022.01.011_bib0064","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejps.2009.06.001","article-title":"Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress","volume":"38","author":"Hawe","year":"2009","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0065","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.xphs.2019.09.026","article-title":"Silicone oil particles in prefilled syringes with human monoclonal antibody, representative of real-world drug products, did not increase immunogenicity in in vivo and in vitro model systems","volume":"109","author":"Joh","year":"2020","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0066","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.xphs.2019.10.025","article-title":"A multicompany assessment of submicron particle levels by NTA and RMM in a wide range of late-phase clinical and commercial biotechnology-derived protein products","volume":"109","author":"Hubert","year":"2020","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0067","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.xphs.2019.10.066","article-title":"Characterization of subvisible particles in biotherapeutic prefilled syringes: the role of polysorbate and protein on the formation of silicone oil and protein subvisible particles after drop shock","volume":"109","author":"Jiao","year":"2020","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2022.01.011_bib0068","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s11095-012-0696-6","article-title":"Mechanistic understanding of protein-silicone oil interactions","volume":"29","author":"Li","year":"2012","journal-title":"Pharm Res"},{"issue":"1-2","key":"10.1016\/j.xphs.2022.01.011_bib0069","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijpharm.2012.03.005","article-title":"The effect of Tween((R)) 20 on silicone oil-fusion protein interactions","volume":"429","author":"Dixit","year":"2012","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2022.01.011_bib0070","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1007\/s11095-013-1028-1","article-title":"Protein-silicone oil interactions: comparative effect of nonionic surfactants on the interfacial behavior of a fusion protein","volume":"30","author":"Dixit","year":"2013","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2022.01.011_bib0071","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.xphs.2017.09.029","article-title":"Understanding protein-interface interactions of a fusion protein at silicone oil-water interface probed by sum frequency generation vibrational spectroscopy","volume":"107","author":"Li","year":"2018","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0072","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1208\/s12248-016-9983-1","article-title":"Particle characterization for a protein drug product stored in pre-filled syringes using micro-flow imaging, archimedes, and quartz crystal microbalance with dissipation","volume":"19","author":"Zheng","year":"2017","journal-title":"AAPS J"},{"issue":"12","key":"10.1016\/j.xphs.2022.01.011_bib0073","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1002\/jps.21778","article-title":"Tungsten-induced protein aggregation: solution behavior","volume":"98","author":"Jiang","year":"2009","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2022.01.011_bib0074","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1007\/s11095-011-0621-4","article-title":"Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity","volume":"29","author":"Seidl","year":"2012","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5731\/pdajpst.2012.00803","article-title":"Interactions between therapeutic proteins and acrylic acid leachable","volume":"66","author":"Liu","year":"2012","journal-title":"PDA J Pharm Sci Technol"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0076","first-page":"98","article-title":"Challenges in the development of pre-filled syringes for biologics from a formulation scientist's point of view","volume":"15","author":"Adler","year":"2012","journal-title":"Am Pharm Rev"},{"key":"10.1016\/j.xphs.2022.01.011_bib0077","article-title":"Prefilled syringes & parenteral contract manufacturing: biologics present a new set of challenges","author":"Dubin","year":"2016","journal-title":"Drug DevelDeliv"},{"issue":"Issue 28","key":"10.1016\/j.xphs.2022.01.011_bib0078","first-page":"34","article-title":"Coated plungers: peace of mind","author":"Grueninger","year":"2011","journal-title":"ONdrugDelivery"},{"issue":"7","key":"10.1016\/j.xphs.2022.01.011_bib0079","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.xphs.2016.04.015","article-title":"Aggregation and particle formation of therapeutic proteins in contact with a novel fluoropolymer surface versus siliconized surfaces: effects of agitation in vials and in prefilled syringes","volume":"105","author":"Teska","year":"2016","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.01.011_bib0080","series-title":"YpsoMate \u2013 The 2-Step Autoinjector","year":"2021"},{"key":"10.1016\/j.xphs.2022.01.011_bib0081","series-title":"Neulasta\u00ae Onpro\u00ae Kit","year":"2021"},{"key":"10.1016\/j.xphs.2022.01.011_bib0082","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejpb.2020.05.016","article-title":"Exploration of temperature and shelf-life dependency of the therapeutically available Insulin Detemir","volume":"152","author":"Beji","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"issue":"1-2","key":"10.1016\/j.xphs.2022.01.011_bib0083","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijpharm.2005.10.024","article-title":"Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298","volume":"308","author":"Zheng","year":"2006","journal-title":"Int J Pharm"},{"issue":"1-2","key":"10.1016\/j.xphs.2022.01.011_bib0084","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijpharm.2011.04.024","article-title":"Probing the mechanism of insulin aggregation during agitation","volume":"413","author":"Malik","year":"2011","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2022.01.011_bib0085","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/19420862.2015.1062193","article-title":"Metal ion interactions with mAbs: Part 1","volume":"7","author":"Glover","year":"2015","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.xphs.2022.01.011_bib0086","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ab.2009.03.027","article-title":"Elevated cleavage of human immunoglobulin gamma molecules containing a lambda light chain mediated by iron and histidine","volume":"389","author":"Ouellette","year":"2009","journal-title":"Anal Biochem"},{"issue":"29","key":"10.1016\/j.xphs.2022.01.011_bib0087","doi-asserted-by":"crossref","first-page":"15394","DOI":"10.1016\/S0021-9258(17)36264-6","article-title":"Nonenzymatic cleavage of proteins by reactive oxygen species generated by dithiothreitol and iron","volume":"260","author":"Kim","year":"1985","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.xphs.2022.01.011_bib0088","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s11095-021-03089-7","article-title":"Metal Ion Interactions with mAbs: Part 2. Zinc-mediated aggregation of IgG1 monoclonal antibodies","volume":"38","author":"Mehta","year":"2021","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2022.01.011_bib0089","first-page":"165","article-title":"Rubber coring of injectable medication vial stoppers: an evaluation of causal factors","volume":"1","author":"Chennell","year":"2016","journal-title":"Pharm Technol Hosp Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0090","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.xphs.2019.10.042","article-title":"Challenges of using closed system transfer devices with biological drug products: an industry perspective","volume":"109","author":"Sreedhara","year":"2020","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0091","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.xphs.2019.07.021","article-title":"Overcoming challenges of implementing closed system transfer device clinical in-use compatibility testing for drug development of antibody drug conjugates","volume":"109","author":"Petoskey","year":"2020","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0092","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5731\/pdajpst.2018.008664","article-title":"A case study to address a gap in the device-to-vial interface stopper push-in by chemo spikes","volume":"73","author":"Zhao","year":"2019","journal-title":"PDA J Pharm Sci Technol"},{"issue":"2","key":"10.1016\/j.xphs.2022.01.011_bib0093","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.xphs.2020.10.047","article-title":"An industry perspective on compatibility assessment of closed system drug-transfer devices for biologics","volume":"110","author":"Besheer","year":"2021","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2022.01.011_bib0094","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1208\/s12248-019-0312-3","article-title":"Interfacial stress in the development of biologics: fundamental understanding, current practice, and future perspective","volume":"21","author":"Li","year":"2019","journal-title":"AAPS J"},{"issue":"4","key":"10.1016\/j.xphs.2022.01.011_bib0095","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.xphs.2016.11.021","article-title":"Shipping-induced aggregation in therapeutic antibodies: utilization of a scale-down model to assess degradation in monoclonal antibodies","volume":"106","author":"Fleischman","year":"2017","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2022.01.011_bib0096","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1208\/s12249-011-9684-0","article-title":"Stability studies needed to define the handling and transport conditions of sensitive pharmaceutical or biotechnological products","volume":"12","author":"Ammann","year":"2011","journal-title":"AAPS PharmSciTech"},{"issue":"Pt A","key":"10.1016\/j.xphs.2022.01.011_bib0097","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejpb.2015.09.016","article-title":"Key interactions of surfactants in therapeutic protein formulations: a review","volume":"97","author":"Khan","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"issue":"11","key":"10.1016\/j.xphs.2022.01.011_bib0098","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1021\/acs.molpharmaceut.5b00311","article-title":"Polysorbate 20 degradation in biopharmaceutical formulations: quantification of free fatty acids, characterization of particulates, and insights into the degradation mechanism","volume":"12","author":"Tomlinson","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2022.01.011_bib0099","series-title":"Evaluation of Piston Movement and Container Integrity Under Severe Storage Conditions in Plastic and Glass Prefilled Syringes","year":"2012"},{"issue":"2","key":"10.1016\/j.xphs.2022.01.011_bib0100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jps.24242","article-title":"Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress","volume":"104","author":"Telikepalli","year":"2015","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2022.01.011_bib0101","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3109\/03639045.2014.917093","article-title":"Effect of X-ray exposure on the pharmaceutical quality of drug tablets using X-ray inspection equipment","volume":"41","author":"Uehara","year":"2015","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.xphs.2022.01.011_bib0102","series-title":"Integrating X-ray Technology into Production","author":"Razzak","year":"2019"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0103","doi-asserted-by":"crossref","first-page":"1685814","DOI":"10.1080\/19420862.2019.1685814","article-title":"Defining the right diluent for intravenous infusion of therapeutic antibodies","volume":"12","author":"Luo","year":"2020","journal-title":"MAbs"},{"issue":"7","key":"10.1016\/j.xphs.2022.01.011_bib0104","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1016\/j.xphs.2019.02.020","article-title":"Contribution of intravenous administration components to subvisible and submicron particles present in administered drug product","volume":"108","author":"Pollo","year":"2019","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0105","doi-asserted-by":"crossref","first-page":"7714","DOI":"10.1038\/s41598-018-25602-6","article-title":"Effectiveness of in-line filters to completely remove particulate contamination during a pediatric multidrug infusion protocol","volume":"8","author":"Perez","year":"2018","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.xphs.2022.01.011_bib0106","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1016\/j.xphs.2017.05.028","article-title":"Protein adsorption to in-line filters of intravenous administration sets","volume":"106","author":"Besheer","year":"2017","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2022.01.011_bib0107","first-page":"271","article-title":"Filters and filtration: a review of mechanisms othat impact cost, product quality and patient safety","volume":"8","author":"Pillai","year":"2016","journal-title":"J Pharm Sci & Res"},{"issue":"1","key":"10.1016\/j.xphs.2022.01.011_bib0108","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jps.22739","article-title":"Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions","volume":"101","author":"Sreedhara","year":"2012","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2022.01.011_bib0109","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11095-020-02859-z","article-title":"Formulation and administration of biological medicinal products","volume":"37","author":"Kramer","year":"2020","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2022.01.011_bib0110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpb.2015.12.003","article-title":"Effect of ambient light on IgG1 monoclonal antibodies during drug product processing and development","volume":"100","author":"Sreedhara","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"10.1016\/j.xphs.2022.01.011_bib0111","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11095-020-02798-9","article-title":"Protein stability and photostability under in vitro vitreal conditions - implications for long acting delivery of protein therapeutics for ocular disease","volume":"37","author":"Mantha","year":"2020","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2022.01.011_bib0112","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11095-020-02784-1","article-title":"Evaluation of different quality-relevant aspects of closed system transfer devices (CSTDs)","volume":"37","author":"Besheer","year":"2020","journal-title":"Pharm Res"},{"issue":"11","key":"10.1016\/j.xphs.2022.01.011_bib0113","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1016\/j.xphs.2017.06.017","article-title":"A formulation development approach to identify and select stable ultra-high-concentration monoclonal antibody formulations with reduced viscosities","volume":"106","author":"Whitaker","year":"2017","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2022.01.011_bib0114","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.xphs.2020.10.036","article-title":"In-Use interfacial stability of monoclonal antibody formulations diluted in saline i.v. bags","volume":"110","author":"Kannan","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.01.011_bib0115","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejpb.2018.05.006","article-title":"On the needle clogging of staked-in-needle pre-filled syringes: Mechanism of liquid entering the needle and solidification process","volume":"128","author":"De Bardi","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"10.1016\/j.xphs.2022.01.011_bib0116","doi-asserted-by":"crossref","first-page":"E501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J"},{"issue":"6","key":"10.1016\/j.xphs.2022.01.011_bib0117","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1023\/B:PHAM.0000029275.41323.a6","article-title":"Structure-immunogenicity relationships of therapeutic proteins","volume":"21","author":"Hermeling","year":"2004","journal-title":"Pharm Res"},{"issue":"12","key":"10.1016\/j.xphs.2022.01.011_bib0118","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/biot.201200065","article-title":"Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins","volume":"7","author":"van Beers","year":"2012","journal-title":"Biotechnol J"},{"issue":"10","key":"10.1016\/j.xphs.2022.01.011_bib0119","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1002\/jps.23244","article-title":"Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins","volume":"101","author":"Rosenberg","year":"2012","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2022.01.011_bib0120","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/1547691X.2013.821564","article-title":"Immunogenicity of therapeutic proteins: influence of aggregation","volume":"11","author":"Ratanji","year":"2014","journal-title":"J Immunotoxicol"},{"issue":"5","key":"10.1016\/j.xphs.2022.01.011_bib0121","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/jps.23935","article-title":"Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin","volume":"103","author":"Torosantucci","year":"2014","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2022.01.011_bib0122","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11095-013-1199-9","article-title":"Oxidation of therapeutic proteins and peptides: structural and biological consequences","volume":"31","author":"Torosantucci","year":"2014","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2022.01.011_bib0123","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.xphs.2015.11.002","article-title":"Immunogenicity of therapeutic protein aggregates","volume":"105","author":"Moussa","year":"2016","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2022.01.011_bib0124","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.xphs.2016.02.031","article-title":"Mouse models for assessing protein immunogenicity: lessons and challenges","volume":"105","author":"Jiskoot","year":"2016","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2022.01.011_bib0125","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1002\/jps.23663","article-title":"Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics","volume":"102","author":"Bi","year":"2013","journal-title":"J Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922000211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922000211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:35:58Z","timestamp":1758360958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354922000211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":125,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0022354922000211"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2022.01.011","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stress Factors in Primary Packaging, Transportation and Handling of Protein Drug Products and Their Impact on Product Quality","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2022.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}